Pressure Ulcers - Pipeline Insight, 2024

This Pressure Ulcers - Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Pressure Ulcers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pressure Ulcers Understanding

Pressure Ulcers: Overview

Decubitus ulcers, also termed bedsores or pressure ulcers, are skin and soft tissue injuries that form as a result of constant or prolonged pressure exerted on the skin. These ulcers occur at bony areas of the body such as the ischium, greater trochanter, sacrum, heel, malleolus (lateral than medial), and occiput. These lesions mostly occur in people with conditions that decrease their mobility making postural change difficult. Jean-Martin Charcot was a French doctor in the 19th century who studied many diseases, including decubitus ulcers. He noticed that patients who developed eschar of the buttocks and sacrum died after some time. He named this lesion decubitus ominous, which meant death was inevitable after developing this lesion.

Pressure Ulcers - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pressure Ulcers pipeline landscape is provided which includes the disease overview and Pressure Ulcers treatment guidelines. The assessment part of the report embraces, in depth Pressure Ulcers commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pressure Ulcers collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Pressure Ulcers R&D. The therapies under development are focused on novel approaches to treat/improve Pressure Ulcers.

This segment of the Pressure Ulcers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pressure Ulcers Drugs
EGT 022: EyeGeneEGT 022 is a RGD motif containing recombinant polypeptide from human-derived protein ADAM-15. It is being developed by EyeGene Inc.

Pressure Ulcers: Therapeutic Assessment

This segment of the report provides insights about the Pressure Ulcers drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pressure Ulcers

There are approx. 8+ key companies which are developing the therapies for Pressure Ulcers. The companies which have their Pressure Ulcers drug candidates in the most advanced stage, i.e. Preclinical include EyeGene.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pressure Ulcers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pressure Ulcers: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pressure Ulcers therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pressure Ulcers drugs.

Pressure Ulcers Report Insights

• Pressure Ulcers Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pressure Ulcers Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pressure Ulcers drugs?
• How many Pressure Ulcers drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pressure Ulcers?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pressure Ulcers therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pressure Ulcers and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Phagelux
• MiMedx
• EyeGene
• Shionogi
• NovaLead Pharma

Key Products

• Bacteriophage therapy
• dHACM PII
• EGT 022
• SR 0379
• NLP 328

This product will be delivered within 2 business days.